Overview

The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.

Eligibility

Inclusion Criteria:

• HCC (diagnosis: histological or radiological)
• Age: 18-80
• Number of lesions 1-3 lesions
• Size of the lesion (or sum of 2-3 lesions) ≥ 4 cm
• Sufficient non-tumorous liver volume (≥ 800 cm3)
• Child Pugh Score: A5-6 or B7-8
• BCLC A or B
• Patient is illegible or refused surgical resection or orthotopic liver transplant
• Blood work (within 2 weeks before registration):
• Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³)
• Platelets ≥50,000 cells/mm³
• AST (and ALT) \< 5 times ULN
• Serum creatinine ≤ ULN or creatinine clearance ≥ 50 mL/min

Exclusion Criteria:

• Evidence of extrahepatic disease (lymph node or distant metastases)
• Evidence of macroscopic vascular invasion
• Evidence of an arterio-portal or arterio-venous fistulas
• History of previous malignancy
• Previous SIRT
• Previous Sorafenib in the last 8 weeks
• Pregnant and lactating females